EMA News
Friday, March 13, 2026
EMA PRAC Warns of Aseptic Meningitis Risk with Ixchiq Vaccine
The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has recommended updating the product information for the chikungunya vaccine Ixchiq to reflect recent evidence of aseptic meningitis risk, particularly in healthy young adults. This follows a safety signal investigation and is part of a regular safety assessment.
Priority review
Guidance
Pharmaceuticals
Source details
Activity
Browse Categories
Agriculture & Food Safety
61
Banking & Finance
163
Consumer Protection
29
Courts & Legal
206
Data Privacy & Cybersecurity
58
Defense & National Security
48
Education
20
Energy
94
Environment
81
Government & Legislation
240
Healthcare
105
Housing
15
Immigration
8
Insurance
16
Labor & Employment
104
Pharma & Drug Safety
68
Securities & Markets
69
Tax
48
Telecom & Technology
34
Trade & Sanctions
113
Transportation
53
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get EMA News alerts
We'll email you when EMA News publishes new changes.